DeepMed Research

Vilazodone

Generic Name: Vilazodone

Brand Names: Viibryd

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₇N_₅O_₂

CAS Number: 163521-12-8

Unique Ingredient Identifier: S239O2OOV3

Background: Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors. Vilazodone may also be associated with less sexual dysfunction and weight gain. Vilazodone was given FDA approval on January 21, 2011.

Indication: 用于治疗成人重度抑郁症（MDD）。

Associated Conditions: Major Depressive Disorder (MDD)

Clinical Trials

Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Paroxetine 20 mg
Drug: Vilazodone 20 mg
Drug: Vilazodone 40 mg
Drug: Placebo

First Posted Date: 2014-03-26

Last Posted Date: 2015-02-12

Lead Sponsor: Forest Laboratories

Target Recruit Count: 202

Registration Number: NCT02097147

Locations: 🇺🇸
Forest Investigative Site 001, Miami, Florida, United States
🇺🇸
Forest Investigative Site 002, Overland Park, Kansas, United States
🇺🇸
Forest Investigative Site 004, Charlottesville, Virginia, United States

and more 1 locations

The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives

Phase 4

Withdrawn

Conditions: Comorbidity
Major Depressive Disorder
Anxiety

Interventions: Drug: Citalopram
Drug: Vilazodone

First Posted Date: 2014-01-06

Last Posted Date: 2016-11-08

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT02028026

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone

Phase 3

Completed

Conditions: Major Depressive Disorder (MDD)

Interventions: Drug: Vilazodone

First Posted Date: 2013-12-19

Last Posted Date: 2015-04-16

Lead Sponsor: Duke University

Target Recruit Count: 70

Registration Number: NCT02015546

Locations: 🇺🇸
Duke University Medical Center / Civitan Building, Durham, North Carolina, United States

Vilazodone for Separation Anxiety Disorder

Phase 4

Completed

Conditions: Separation Anxiety Disorder

Interventions: Drug: Placebo
Drug: Vilazodone

First Posted Date: 2013-12-03

Last Posted Date: 2018-03-07

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 24

Registration Number: NCT01999920

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Vilazodone

First Posted Date: 2013-06-14

Last Posted Date: 2019-12-24

Lead Sponsor: Forest Laboratories

Target Recruit Count: 529

Registration Number: NCT01878292

Locations: 🇺🇸
Forest Investigative Site 054, Baltimore, Maryland, United States
🇺🇸
Forest Investigative Site 034, Oakland Park, Florida, United States
🇺🇸
Forest Investigative Site 030, Roswell, Georgia, United States

and more 49 locations

Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?

Phase 4

Terminated

Conditions: Sexual Dysfunction
Major Depressive Disorder

Interventions: Drug: Vilazodone
Drug: Sertraline

First Posted Date: 2013-05-17

Last Posted Date: 2016-08-25

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 4

Registration Number: NCT01856127

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder

Phase 3

Completed

Conditions: Generalized Anxiety Disorder

Interventions: Drug: Placebo
Drug: Vilazodone

First Posted Date: 2013-05-01

Last Posted Date: 2019-12-18

Lead Sponsor: Forest Laboratories

Target Recruit Count: 415

Registration Number: NCT01844115

Locations: 🇺🇸
Forest Investigative Site 023, Birmingham, Alabama, United States
🇺🇸
Forest Investigative Site 013, Phoenix, Arizona, United States
🇺🇸
Forest Investigative Site 001, Costa Mesa, California, United States

and more 33 locations

Vilazodone for Corticosteroid-Induced Memory Impairment

Phase 2

Completed

Conditions: Memory Impairment

Interventions: Drug: Vilazodone
Drug: Placebo
Drug: Hydrocortisone

First Posted Date: 2013-04-10

Last Posted Date: 2019-04-11

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 24

Registration Number: NCT01828515

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

Double-Blind Treatment of Major Depressive Disorder With Vilazodone

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Vilazodone
Drug: Citalopram

First Posted Date: 2012-12-05

Last Posted Date: 2023-02-23

Lead Sponsor: University of Chicago

Target Recruit Count: 79

Registration Number: NCT01742832

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

The Role of Antidepressants or Antipsychotics in Preventing Psychosis

Not Applicable

Withdrawn

Conditions: Psychotic Disorder

Interventions: Drug: Antidepressant
Drug: Antipsychotic

First Posted Date: 2012-11-09

Last Posted Date: 2014-05-26

Lead Sponsor: St. Luke's-Roosevelt Hospital Center

Registration Number: NCT01724372

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy